Figlia Vanessa, Simonetto Cristoforo, Eidemüller Markus, Naccarato Stefania, Sicignano Gianluisa, De Simone Antonio, Ruggieri Ruggero, Mazzola Rosario, Matuschek Christiane, Bölke Edwin, Pazos Montserrat, Niyazi Maximilian, Belka Claus, Alongi Filippo, Corradini Stefanie
Advanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Negrar, Italy.
Institute of Radiation Medicine, Helmholtz Center Munich, Munich, Germany.
Breast Care (Basel). 2021 Aug;16(4):358-367. doi: 10.1159/000509779. Epub 2020 Oct 19.
The aim of the present study was to estimate the impact of the addition of internal mammary chain (IMC) irradiation in node-positive left-sided breast cancer (BC) patients undergoing regional nodal irradiation (RNI) and comparatively evaluate excess relative and absolute risks of radiation-induced lung cancer/BC and ischaemic heart disease for intensity-modulated radiotherapy (IMRT) versus 3D conformal radiotherapy (3D-CRT).
Four treatment plans were created (3D-CRT and IMRT -/+ IMC) for each of the 10 evaluated patients, and estimates of excess relative risk (ERR) and 10-year excess absolute risk (EAR) were calculated for radiation-induced lung cancer/BC and coronary events using linear, linear-exponential and plateau models.
The addition of IMC irradiation to RNI significantly increased the dose exposure of the heart, lung and contralateral breast using both techniques, increasing ERR for secondary lung cancer (58 vs. 44%, = 0.002), contralateral BC (49 vs. 31%, = 0.002) and ischaemic heart disease (41 vs. 27%, = 0.002, IMRT plans). IMRT significantly reduced the mean cardiac dose and mean lung dose as compared to 3D-CRT, decreasing ERR for major coronary events (64% 3D-CRT vs. 41% IMRT, = 0.002) and ERR for secondary lung cancer (75 vs. 58%, = 0.004) in IMC irradiation, without a significant impact on secondary contralateral BC risks.
Although IMC irradiation has been shown to increase survival rates in node-positive BC patients, it increased dose exposure of organs at risk in left-sided BC, resulting in significantly increased risks for secondary lung cancer/contralateral BC and ischaemic heart disease. In this setting, the adoption of IMRT seems advantageous when compared to 3D-CRT.
本研究的目的是评估在接受区域淋巴结照射(RNI)的左侧淋巴结阳性乳腺癌(BC)患者中增加内乳链(IMC)照射的影响,并比较强度调制放疗(IMRT)与三维适形放疗(3D-CRT)在辐射诱发肺癌/BC和缺血性心脏病方面的超额相对风险和绝对风险。
为10名评估患者中的每一位创建了四个治疗计划(3D-CRT和IMRT -/+ IMC),并使用线性、线性指数和平原模型计算辐射诱发肺癌/BC和冠状动脉事件的超额相对风险(ERR)和10年超额绝对风险(EAR)。
两种技术在RNI中增加IMC照射均显著增加了心脏、肺和对侧乳腺的剂量暴露,增加了继发性肺癌的ERR(58%对44%,P = 0.002)、对侧BC的ERR(49%对31%,P = 0.002)和缺血性心脏病的ERR(41%对27%,P = 0.002,IMRT计划)。与3D-CRT相比,IMRT显著降低了平均心脏剂量和平均肺剂量,降低了IMC照射中主要冠状动脉事件的ERR(3D-CRT为64%,IMRT为41%,P = 0.002)和继发性肺癌的ERR(75%对58%,P = 0.004),对对侧继发性BC风险无显著影响。
尽管已证明IMC照射可提高淋巴结阳性BC患者的生存率,但它增加了左侧BC中危险器官的剂量暴露,导致继发性肺癌/对侧BC和缺血性心脏病的风险显著增加。在这种情况下,与3D-CRT相比,采用IMRT似乎更具优势。